Prascend for Horses Cost & Cushing's PPID: 2026 Sourcing Guide
Essential Pricing Takeaways
- • Prascend (pergolide mesylate) is the only FDA-approved medication specifically formulated and licensed to treat PPID in equines.
- • Daily pergolide therapy stimulates dopamine receptors, halting pituitary melanotrope hypertrophy and dramatically reducing excessive ACTH secretion.
- • Purchasing 160-tablet economy boxes through accredited online pet pharmacies lowers the daily cost-to-treat from $3.25 to approximately $2.10 per tablet.
- • Routine diagnostic blood testing (resting baseline ACTH and TRH stimulation tests) must be performed every 6 months to adjust dosage tiers.
Pituitary Pars Intermedia Dysfunction (PPID), historically referred to as equine Cushing's disease, is the single most common neuroendocrine disorder diagnosed in horses, ponies, and donkeys over the age of fifteen.
Prascend (pergolide mesylate) is the premier, FDA-approved dopaminergic agonist that restores neurochemical regulation to the pituitary gland, preventing devastating secondary complications including chronic laminitis, recurrent infections, and catastrophic muscle wasting.
Because PPID is a permanent, progressive condition requiring lifelong daily medication, optimizing sourcing costs is crucial for owners. Transitioning from small clinic counter blister packs to 160-count economy boxes through licensed mail-order pharmacies saves between $450 and $700 every year.
Prascend (Pergolide Mesylate) Pricing Guide: Clinic Counter vs. Mail-Order Economies
| Pack Size & Strength | Active Molecule | Dosing Schedule | Clinic Dispensing | Online Sourced | Savings Benchmark | Action |
|---|---|---|---|---|---|---|
| Prascend 1mg (60-Tablet Box) | Pergolide Mesylate 1.0mg | Scored Tablets (1 Box) | $195.00 / box | $148.00 / box | Save $47.00 Online ($148.00) | Check Price → |
| Prascend 1mg (160-Tablet Value Pack) | Pergolide Mesylate 1.0mg | 16 Blister Strips (160 Tabs) | $485.00 / box | $349.00 / box | Save $136.00 Online ($349.00) | Check Price → |
| Prascend Annual Supply (365 Tablets) | Pergolide Mesylate 1.0mg | Full 12-Month Sourcing | $1,110.00 / yr | $795.00 / yr | Save $315.00 / Year ($795.00) | Check Price → |
| Compounded Pergolide (Bulk Powder) | Pergolide Mesylate (Unregulated) | Liquid or Bulk Powder | $135.00 / 60-day | $98.00 / 60-day | High Potency Risk ($98.00) | Check Price → |
*Pricing figures are audited periodically. Destination pharmacies may alter promotions or manufacturer rebates without advance notice.
Top Recommended Options & Discounts
Heartland Vet Supply (Prascend 160-Tablet Economy Pack)
Best For: Senior horse owners seeking the lowest per-tablet cost on long-term daily Cushing's management
- ✓ Full manufacturer batch-tested blister packaging ensuring 100% molecular potency
- ✓ Seamless recurring auto-refill schedules so horses never miss a daily morning dose
- ✓ Licensed US veterinary pharmacist support for dosing and titration inquiries
Canada Pet Care (Equine Endocrine & Senior Care)
Best For: Stable owners managing multiple senior horses diagnosed with pituitary dysfunction
- ✓ Direct delivery of authentic veterinary pharmaceuticals with zero handling surcharges
- ✓ Volume savings discounts on multi-box orders for equestrian centers and boarding barns
- ✓ Guaranteed fresh expiration dates for stable long-term medication storage
Calculate Exact Dose & Cost-Per-Day by Pet Weight
Adjust the weight slider to determine the required clinical dose tier, monthly supply costs, and annual mail-order savings.
*Prices audited across licensed dispensaries. Direct electronic prescription transfer supported.
Pathophysiology of PPID: Dopaminergic Neurodegeneration in Equines
Equine Cushing's is fundamentally a neurodegenerative condition rather than an adrenal tumor (which is common in canines). As horses age, dopaminergic neurons in the periventricular nucleus of the hypothalamus experience chronic oxidative stress and degenerate.
Without dopamine's natural inhibitory control, the melanotropes of the intermediate lobe of the pituitary gland hypertrophy and hyperplasia, overproducing adrenocorticotropic hormone (ACTH), alpha-melanocyte-stimulating hormone (alpha-MSH), and beta-endorphins. Prascend acts as a synthetic dopamine substitute, binding to dopamine D2 receptors and signaling the pituitary gland to reduce ACTH secretion back toward baseline.
Managing the "Pergolide Veil": Clinical Acclimation Strategies
During the first 7 to 14 days of initiating Prascend therapy, approximately 15% to 20% of horses experience a transient syndrome known among equine clinicians as the "pergolide veil." Affected horses may exhibit inappetence, mild lethargy, dullness, or reluctance to finish their daily concentrate feed.
Equine veterinarians recommend starting with a stepped dosing approach: administering a half-tablet (0.5mg) daily for the first 5 to 7 days before escalating to the full 1.0mg maintenance target. If appetite suppression occurs, briefly stepping down the dose or splitting administration between morning and evening typically resolves symptoms as the central nervous system acclimates.
Seasonal ACTH Surges and Fall Diagnostic Timing
All horses experience a natural circannual elevation in plasma ACTH during late summer and autumn (August through November) as part of an evolutionary preparation for winter. In horses with subclinical or diagnosed PPID, this autumn surge is exaggerated up to fivefold, dramatically increasing the risk of seasonal pasture laminitis.
Diagnostic blood tests conducted in the fall must be evaluated against established seasonal reference ranges rather than spring baseline values. Horse owners should partner with their veterinarian to monitor ACTH levels each September or October, frequently adjusting Prascend doses upward by 0.5mg to 1.0mg to protect sensitive lamellar hoof structures throughout the peak risk window.